Evolus signs option deal with private partner for sustained-release injectable hair restoration program
EOLS•Evolus entered an option agreement with a privately held developer, paying $1.5 million initially and agreeing to stage-gated development milestone payments. Evolus may acquire 100% of the program assets after an initial clinical dataset.
1. Option agreement
Evolus entered an option agreement with a privately held developer for a sustained-release injectable hair restoration treatment. The initial option payment totals $1.5 million, with additional stage-gated payments tied to development milestones.
2. Development timeline
Evolus will support development, including an initial clinical proof-of-concept study, and has an option to acquire 100% of the program assets after an initial clinical dataset. Formulation work is expected to continue through 2027, with first-in-human studies anticipated to start afterward.
